2017 November

A Systematic Review and Meta-analysis

Key Points

Question What is the prevalence of foetal alcohol spectrum disorder among children and youth in the general population?

Findings In this meta-analysis of 24 unique studies and 1416 unique children and youth with foetal alcohol spectrum disorder, approximately 8 of 1000 in the general population had foetal alcohol spectrum disorder, and 1 of every 13 pregnant women who consumed alcohol during pregnancy delivered a child with foetal alcohol spectrum disorder. The prevalence of foetal alcohol spectrum disorder was found to be notably higher among special populations.

Meaning The prevalence of foetal alcohol spectrum disorder among children and youth in the general population exceeds 1% in 76 countries, which underscores the need for universal prevention initiatives targeting maternal alcohol consumption, screening protocols, and improved access to diagnostic services, especially in special populations.

Abstract

Importance Prevalence estimates are essential to effectively prioritize, plan, and deliver health care to high-needs populations such as children and youth with fetal alcohol spectrum disorder (FASD). However, most countries do not have population-level prevalence data for FASD.

Objective To obtain prevalence estimates of FASD among children and youth in the general population by country, by World Health Organization (WHO) region, and globally.

Data Sources MEDLINE, MEDLINE in process, EMBASE, Education Resource Information Center, Cumulative Index to Nursing and Allied Health Literature, Web of Science, PsychINFO, and Scopus were systematically searched for studies published from November 1, 1973, through June 30, 2015, without geographic or language restrictions.

Study Selection Original quantitative studies that reported the prevalence of FASD among children and youth in the general population, used active case ascertainment or clinic-based methods, and specified the diagnostic guideline or case definition used were included.

Data Extraction and Synthesis Individual study characteristics and prevalence of FASD were extracted. Country-specific random-effects meta-analyses were conducted. For countries with 1 or no empirical study on the prevalence of FASD, this indicator was estimated based on the proportion of women who consumed alcohol during pregnancy per 1 case of FASD. Finally, WHO regional and global mean prevalence of FASD weighted by the number of live births in each country was estimated.

Main Outcomes and Measures Prevalence of FASD.

Results A total of 24 unique studies including 1416 unique children and youth diagnosed with FASD (age range, 0-16.4 years) were retained for data extraction. The global prevalence of FASD among children and youth in the general population was estimated to be 7.7 per 1000 population (95% CI, 4.9-11.7 per 1000 population).

The WHO European Region had the highest prevalence (19.8 per 1000 population; 95% CI, 14.1-28.0 per 1000 population), and the WHO Eastern Mediterranean Region had the lowest (0.1 per 1000 population; 95% CI, 0.1-0.5 per 1000 population).

Of 187 countries, South Africa was estimated to have the highest prevalence of FASD at 111.1 per 1000 population (95% CI, 71.1-158.4 per 1000 population), followed by Croatia at 53.3 per 1000 population (95% CI, 30.9-81.2 per 1000 population) and Ireland at 47.5 per 1000 population (95% CI, 28.0-73.6 per 1000 population).

Conclusions and Relevance

Globally, FASD is a prevalent alcohol-related developmental disability that is largely preventable. The findings highlight the need to establish a universal public health message about the potential harm of prenatal alcohol exposure and a routine screening protocol. Brief interventions should be provided, where appropriate.

Source: https://jamanetwork.com/journals/jamapediatrics/article-abstract/2649225

Abstract

IMPORTANCE:

Over the last 25 years, illicit cannabis use and cannabis use disorders have increased among US adults, and 28 states have passed medical marijuana laws (MML). Little is known about MML and adult illicit cannabis use or cannabis use disorders considered over time.

OBJECTIVE:

To present national data on state MML and degree of change in the prevalence of cannabis use and disorders.

DESIGN, PARTICIPANTS, AND SETTING:

Differences in the degree of change between those living in MML states and other states were examined using 3 cross-sectional US adult surveys: the National Longitudinal Alcohol Epidemiologic Survey (NLAES; 1991-1992), the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC; 2001-2002), and the National Epidemiologic Survey on Alcohol and Related Conditions-III (NESARC-III; 2012-2013). Early-MML states passed MML between NLAES and NESARC (“earlier period”). Late-MML states passed MML between NESARC and NESARC-III (“later period”).

MAIN OUTCOMES AND MEASURES:

Past-year illicit cannabis use and DSM-IV cannabis use disorder.

RESULTS:

Overall, from 1991-1992 to 2012-2013, illicit cannabis use increased significantly more in states that passed MML than in other states (1.4-percentage point more; SE, 0.5; P = .004), as did cannabis use disorders (0.7-percentage point more; SE, 0.3; P = .03).

In the earlier period, illicit cannabis use and disorders decreased similarly in non-MML states and in California (where prevalence was much higher to start with). In contrast, in remaining early-MML states, the prevalence of use and disorders increased.

Remaining early-MML and non-MML states differed significantly for use (by 2.5 percentage points; SE, 0.9; P = .004) and disorder (1.1 percentage points; SE, 0.5; P = .02). In the later period, illicit use increased by the following percentage points: never-MML states, 3.5 (SE, 0.5); California, 5.3 (SE, 1.0); Colorado, 7.0 (SE, 1.6); other early-MML states, 2.6 (SE, 0.9); and late-MML states, 5.1 (SE, 0.8). Compared with never-MML states, increases in use were significantly greater in late-MML states (1.6-percentage point more; SE, 0.6; P = .01), California (1.8-percentage point more; SE, 0.9; P = .04), and Colorado (3.5-percentage point more; SE, 1.5; P = .03).

Increases in cannabis use disorder, which was less prevalent, were smaller but followed similar patterns descriptively, with change greater than never-MML states in California (1.0-percentage point more; SE, 0.5; P = .06) and Colorado (1.6-percentage point more; SE, 0.8; P = .04).

CONCLUSIONS AND RELEVANCE:

Medical marijuana laws appear to have contributed to increased prevalence of illicit cannabis use and cannabis use disorders. State-specific policy changes may also have played a role. While medical marijuana may help some, cannabis-related health consequences associated with changes in state marijuana laws should receive consideration by health care professionals and the public.

Source: JAMA Psychiatry. 2017 Jun 1;74(6):579-588. doi: 10.1001/jamapsychiatry.2017.0724.

For a long time, those in medicine and the law have been concerned about a link between cannabis and violence.

This has been largely dismissed by the pro-drugs lobby as an association, not proof of a cause. The difference is important to scientific enquiry, as revealed by a telling example given recently by Professor Robert Pickard, a former government advisor.

He says the rise in deaths of hedgehogs on the roads since the end of World War II mirrors the rise in television sales, but it would be daft to suggest that TVs are killing hedgehogs: it’s an association, not a cause.

The evidence linking cannabis and violent crime is compelling: regular use of the drug doubles the risk of a psychotic episode or schizophrenia. And time and again, courts hear how people have become psychotic after smoking cannabis and, in the grips of paranoia and delusions, have murdered someone. The gallery of victims should shame those in the liberal elite who insist there’s no definitive evidence of cause and effect.

But a new study has now provided just this. Researchers followed 1,100 patients for a year after discharge from a psychiatric hospital and those who used cannabis were two-and-a-half times more likely to be violent.

So now there’s clear proof of a causative link, have we witnessed a volte-face from the pro-cannabis lobby? Of course we haven’t, because it was never really about the science.

They want to smoke cannabis, and as soon as science brings doing this into question, they simply brush it aside. Particularly frustrating are the smug, ageing hippies who claim that because they’re still here, it must be fine. They look back on a youth spent smoking spliffs with pathetic, misplaced nostalgia, and fail to realise that, not only did plenty of people not make it through the Sixties and Seventies unscathed, but the super-strong cannabis of today is almost an entirely different product.

How many more lives must be ruined before the pro-drugs lobby admit they got it wrong?

Source: http://www.dailymail.co.uk/health/article-4957554/An-uncomfortable-truth-not-life-worth-living.html#ixzz4uppapuW9

The Liberal government, thanks to Justin Trudeau’s mindless statements during the federal election of 2015, became committed to legalizing the recreational use of marijuana. The purpose of this initiative was to encourage millennials to vote for the Liberal Party.

Like many of its other policies, the Liberal government was clueless about the unintended consequences of this promise. For example, it has yet to solve the problem that has arisen because Canada ratified UN drug treaties that prohibit the use of marijuana. Further, S. 33 of the UN Convention on the Rights of the Child (CRC) specifically states that it is the responsibility of governments to protect children from the use and trafficking of drugs:

33. Parties shall take all appropriate measures, including legislative, administrative, social and educational measures, to protect children from the illicit use of narcotic drugs and psychotropic substances as defined in the relevant international treaties, and to prevent the use of children in their illicit production and trafficking of such substances.

The CRC defines “child” as anyone under 18 years of age. However, once marijuana is legalized, it becomes normalized and becomes acceptable. As a result, adolescents under the age of 18 years will have access to it, as they have easy access, today, to cigarettes.

The Liberals are merrily proceeding with their legalization of marijuana, ignoring their treaty obligations as well as many other serious problems inherent with the legalization.

Unfortunately, the government thinks it cannot back down from its proposal on marijuana as its credibility is already seriously on the line with its accumulating failures on other policies. These include the defeat of electoral reform; the enormous, accumulating national debt, far in excess of what had been promised; the incompetence of the Murdered and Missing Indigenous Women Inquiry; failure to provide transparency and honesty, insisting on continuing with its pay-for-access scheme for corporate high rollers; the flaunting of regulations by Trudeau to vacation with billionaire, the Imam Aga Khan, in the latter’s private island, and the $10.5 million award to terrorist Omar Khadr, who killed an American soldier and blinded another in Afghanistan. Under all these circumstances, it is not unreasonable to describe the Trudeau government as dumb and dumber, as the Liberal blunders are piling up.

Despite this, on April 13, 2017, the Liberal government tabled legislation on marijuana. It provides only a vague and little considered framework for the sale, distribution and possession of it. This framework is based on the federal government’s use of its criminal law provisions to supposedly provide “protection of public health”. This is why Trudeau has been going across the country loudly proclaiming that the objective of his marijuana legislation is “to reduce harm to Canadians” and to “decrease the black market of marijuana”. These comments are nothing more than mindless prattle.

The government is ignoring the reality of recreational marijuana use which occurred in Colorado when it legalized recreational marijuana in 2013. Since that time, Colorado has experienced:

· Marijuana use by Colorado youth between the ages of 12 and 17 years old increased by 20%; this was 74% higher than the national average of that age group;

· Marijuana use of university age youths increased by 17%;

· Marijuana use by adults age 26+ years old increased 63% in comparison to an increase nationally of 21%;

· In 2014 when retail marijuana businesses began operating in Colorado, there was a 32% increase in marijuana related traffic deaths. During the same period of time, alltraffic deaths increased by only 8%. Marijuana related traffic deaths were approximately 20% of all traffic deaths;

· There was a 29% increase in the number of marijuana related emergency room visits in 2014 and a 38% increase in the number of marijuana related hospitalizations;

· During the years 2013-2014, the average number of children exposed to marijuana was 31 per year. This was an increase of 138%;

· According to the Colorado Attorney General, legalization of marijuana did not reduce black market marijuana activity “the criminals are still selling on the black market…. We have plenty of cartel activity and plenty of illegal activity that has not decreased at all”; and

· Homelessness in Colorado surged by 50% with 20 to 30% of newcomers living in shelters, having moved to Colorado to have easy access to marijuana.

Trudeau and his government apparently haven’t even read their own Health Canada Website, which lists the risks of marijuana to include:

· Risks to health, some of which may not be known or fully understood. Studies supporting the safety and efficacy of cannabis for therapeutic purposes are limited and do not meet the standard required by the Food and Drug Regulations for marketed drugs in Canada.

· Smoking cannabis is not recommended. Do not smoke or vapourize cannabis in the presence of children.

· Using cannabis or any cannabis product can impair concentration, ability to think and make decisions, reaction time and coordination. This can affect your motor skills, including ability to drive. It can also increase anxiety and cause panic attacks, and in some cases cause paranoia and hallucinations.

· Cognitive impairment may be greatly increased when cannabis is consumed along with alcohol or other drugs which affect the activity of the nervous system (e.g. opioids, sleeping pills, other psychoactive drugs)

The warning goes on to list specifically when cannabis should never be used by anyone:

· under the age of 25

· who has serious liver, kidney, heart or lung disease

· who has a personal or family history of serious mental disorder such as schizophrenia, psychosis, depression, or bipolar disorder

· who is pregnant, is planning to get pregnant, or is breast-feeding

· who is a man who wishes to start a family

· who has a history of alcohol or drug abuse or substance dependence

In June 2016, ignoring this crucial information, Trudeau established a Task Force to make recommendations on marijuana use. The Committee was headed by former Liberal Justice Minister Anne McLellan. The bad news was that the nine-member Committee included the controversial Dr. Perry Kendall, who, both as Ontario Medical Officer of Health and BC Provincial Health Officer, has advocated for legalization of drugs. In June, 2010, Dr. Kendall claimed that the use of the drug ecstasy can be “safe” when consumed “responsibly”. In 2016, Dr. Kendall called for the decriminalization of personal drug use and possession.

The Committee’s Report, released in December, 2016, could have been written by the marijuana industry. It is void of concerns for public safety and, if implemented, will cause damage to generations of Canadians to the benefit of the marijuana industry.

The Committee recommended that the age of majority, that is 18, be set for the use of marijuana (nineteen years for those in provinces where that is the age of majority).

On May 29th, 2017 an alarmed Canadian Medical Association (CMA), in an editorial in its Journal, stated that current research shows the brain doesn’t reach maturity until around age 25. The CMA editorial referred to the fact that the 9% risk of developing dependence over a lifetime rises to 17% if marijuana use is started in the teen years.

The CMA recommends that the government raise the legal age for buying marijuana to 21, and that it restrict the quantity and potency of the marijuana available to those under 25 years of age.

The Canadian Paediatric Society position paper on the effects of cannabis on children and youth cites serious potential effects, such as: increased presence of mental illness, including depression, anxiety and psychosis; diminished school performance and lifetime achievement; increased risk of tobacco smoking; impaired neurological development and cognitive decline; and a risk of addiction.

In 2010, Canadian youth were ranked No. 1 for cannabis use among 43 countries in Europe and North America. Are we trying to maintain this record?

The federal Task Force also recommended that individuals be allowed to possess 30 grams of marijuana and be permitted to cultivate marijuana for non-medical purposes providing it is limited to four plants per residence, and has the maximum height limit of 100 centimetres. No doubt the police will be knocking on doors with their measuring sticks to ensure that the width and height of the marijuana plants conform to the law.

Just like the Big Tobacco Industry before it, the Big Marijuana Industry is pumping up its corporate growers, in anticipation of grabbing billions of dollars in the growing, distribution and selling of pot across the country. Tobacco smoking is the second biggest risk factor for early death and disability after high blood pressure. Fortunately, because of intense advertising against tobacco smoking, its prevalence has dropped from 35% to 25% among men and from 8% to 5% among women. What on earth then, are we doing by reversing ourselves and adding dangerous marijuana smoke to the deadly mix?

Provinces Concerned About the Marijuana Proposal

Each of the provinces will be required to implement its own rules and restrictions in respect of the distribution and sale of marijuana. This means the provinces will have the last say on the method of sale and point-of-sale restrictions, having regard to the key objective of the federal legislation – supposedly, to prevent or reduce harm to Canadians. In deciding their own rules, Houdini wouldn’t be able to accomplish this. Neither are the provinces likely to reap the supposed vast profits from the sale of marijuana. The provinces are rightly skeptical about any such windfall since taxes on pot are expected to stay low to ensure the regulated market elbows out illegal dealers.

It is significant that on November 1, 2016, the Parliamentary Budget Officer (PBO), Jean-Denis Frechette, released a 77 page study entitled, “Legalized Cannabis: Fiscal Considerations”, which states that the federal government may have little fiscal space to heavily tax cannabis the way it does tobacco, without pushing the legal price well beyond that of currently illicit pot. Price legal pot too high and the black market will continue to flourish; too low and governments could be seen to be encouraging its use.

The PBO projects that sales tax revenue in 2018 could be as low as $356 million and as high as $959 million, with a likely take of about $618 million based on legalized retail cannabis selling for $9 per gram – in line with current street prices.

In addition, health care costs are expected to soar with the legalized use of recreational marijuana. As an example, a new study presented to the Pediatric Academic Societies in 2016, found that one in six toddlers admitted to a Colorado hospital with coughing, wheezing and other symptoms of bronchiolitis tested positive for marijuana exposure.

The Liberal government hopes to have this marijuana muddle all sorted out by July 1, 2018, disregarding the harm to society caused by this legislation. What seems to matter to this government, only, is that millennials vote for the party in the 2019 federal election – even if they are all spaced-out from the use of marijuana!

The Liberal government is reckless and utterly irresponsible in bringing this marijuana legislation forward.

Reality Volume XXXVI Issue No. 10 October 2017 Source: http://www.realwomenofcanada.ca/big-bad-liberal-marijuana-muddle/

Researchers from the McGill Group for Suicide Studies, based at the Douglas Mental Health University Institute and McGill University’s Department of Psychiatry, have just published research in the American Journal of Psychiatry that suggests that the long-lasting effects of traumatic childhood experiences, like severe abuse, may be due to an impaired structure and functioning of cells in the anterior cingulate cortex. This is a part of the brain which plays an important role in the regulation of emotions and mood.

The researchers believe that these changes may contribute to the emergence of depressive disorders and suicidal behaviour.

Crucial insulation for nerve fibres builds up during first two decades of life

For the optimal function and organization of the brain, electrical signals used by neurons may need to travel over long distances to communicate with cells in other regions. The longer axons of this kind are generally covered by a fatty coating called myelin. Myelin sheaths protect the axons and help them to conduct electrical signals more efficiently. Myelin builds up progressively (in a process known as myelination) mainly during childhood, and then continue to mature until early adulthood.

Earlier studies had shown significant abnormalities in the white matter in the brains of people who had experienced child abuse. (White matter is mostly made up of thousands of myelinated nerve fibres stacked together.) But, because these observations were made by looking at the brains of living people using MRI, it was impossible to gain a clear picture of the white matter cells and molecules that were affected.

To gain a clearer picture of the microscopic changes which occur in the brains of adults who have experienced child abuse, and thanks to the availability of brain samples from the Douglas-Bell Canada Brain Bank (where, as well as the brain matter itself there is a lot of information about the lives of their donors) the researchers were able to compare post-mortem brain samples from three different groups of adults: people who had committed suicide who suffered from depression and had a history of severe childhood abuse (27 individuals); people with depression who had committed suicide but who had no history of being abused as children (25 individuals); and brain tissue from a third group of people who had neither psychiatric illnesses nor a history of child abuse (26 people).

Impaired neural connectivity may affect the regulation of emotions

The researchers discovered that the thickness of the myelin coating of a significant proportion of the nerve fibres was reduced ONLY in the brains of those who had suffered from child abuse. They also found underlying molecular alterations that selectively affect the cells that are responsible for myelin generation and maintenance. Finally, they found increases in the diameters of some of the largest axons among only this group and they speculate that together, these changes may alter functional coupling between the cingulate cortex and subcortical structures such as the amygdala and nucleus accumbens (areas of the brain linked respectively to emotional regulation and to reward and satisfaction) and contribute to altered emotional processing in people who have been abused during childhood.

The researchers conclude that adversity in early life may lastingly disrupt a range of neural functions in the anterior cingulate cortex. And while they don’t yet know where in

the brain and when during development, and how, at a molecular level these effects are sufficient to have an impact on the regulation of emotions and attachment, they are now planning to explore this in further research.

Source: http://www.mcgill.ca/newsroom/channels/news/child-abuse-affects-brain-wiring-270024

US life expectancy fell because of the opioid crisis. (Reuters/Adrees Latif)

September 28, 2017 The opioid crisis in the United States is killing nearly one hundred people per day. Some areas are particularly hard hit, leaving officials to deal with constantly multiplying bodies of those claimed by overdose. In Ohio, morgues keep running out of space, forcing authorities to use temporary cold-storage trailers instead. In New Hampshire, medical examiners can’t handle the influx of bodies, making them unable to perform routine autopsies.

Add to that a new, terribly sad number: in West Virginia, officials had to spend nearly $1 million on the transportation of corpses in the fiscal year that ended June 30. Authorities told the Charleston-Gazette Mail that the number of body transports nearly doubled from 2015 to 2017, with a record 880 people dying in the state of overdose last year—the highest rate in the US. One embalmer had to come out of retirement three years ago to help deal with the amount of bodies.

Each death requires at least two trips—to the morgue and to the funeral home. With only two state-run morgues, long trips become costly. West Virginia lawmakers had to approve an additional $500,000 in funding to transport the dead this year. With body transport becoming such a big business—$881,620 paid to private contractors in fiscal year 2017—some improprieties emerged as well. A company that at one point controlled 94% of the state’s business has recently been suspended for a potential and alleged breach of confidentiality, the Charleston Gazette-Mail reported.

The opioid crisis has reached such dire proportions in the US that a recent analysis published in the Journal of the American Medical Association said it cut the life expectancy in the US by 2.5 months. The total estimates of the epidemic’s cost to the economy vary, from $25 billion to even $150 billion a year, when you consider the cost of a lost life (paywall).

The Trump administration promised to take on the issue, with the president himself saying it was a “national emergency,” but no concrete steps have been made yet—including a formal declaration that the epidemic is a national emergency, which would unlock resources that could help.

Source: Reuters . September 28, 2017

Objective:

The authors sought to determine whether cannabis use is associated with a change in the risk of incident nonmedical prescription opioid use and opioid use disorder at 3-year follow-up.

Method:

The authors used logistic regression models to assess prospective associations between cannabis use at wave 1 (2001–2002) and nonmedical prescription opioid use and prescription opioid use disorder at wave 2 (2004–2005) of the National Epidemiologic Survey on Alcohol and Related Conditions. Corresponding analyses were performed among adults with moderate or more severe pain and with nonmedical opioid use at wave 1. Cannabis and prescription opioid use were measured with a structured interview (the Alcohol Use Disorder and Associated Disabilities Interview Schedule–DSM-IV version). Other covariates included age, sex, race/ethnicity, anxiety or mood disorders, family history of drug, alcohol, and behavioral problems, and, in opioid use disorder analyses, nonmedical opioid use.

Results:

In logistic regression models, cannabis use at wave 1 was associated with increased incident nonmedical prescription opioid use (odds ratio=5.78, 95% CI=4.23–7.90) and opioid use disorder (odds ratio=7.76, 95% CI=4.95–12.16) at wave 2. These associations remained significant after adjustment for background characteristics (nonmedical opioid use: adjusted odds ratio=2.62, 95% CI=1.86–3.69; opioid use disorder: adjusted odds ratio=2.18, 95% CI=1.14–4.14). Among adults with pain at wave 1, cannabis use was also associated with increased incident nonmedical opioid use (adjusted odds ratio=2.99, 95% CI=1.63–5.47) at wave 2; it was also associated with increased incident prescription opioid use disorder, although the association fell short of significance (adjusted odds ratio=2.14, 95% CI=0.95–4.83). Among adults with nonmedical opioid use at wave 1, cannabis use was also associated with an increase in nonmedical opioid use (adjusted odds ratio=3.13, 95% CI=1.19–8.23).

Conclusions:

Cannabis use appears to increase rather than decrease the risk of developing nonmedical prescription opioid use and opioid use disorder.

Source: http://ajp.psychiatryonline.org/doi/abs/10.1176/appi.ajp.2017.17040413

NEW REPORT BY NATIONAL FAMILIES IN ACTION RIPS THE VEIL OFF THE MEDICAL MARIJUANA INDUSTRY

Research Traces the Money Trail and Reveals the Motivation Behind Marijuana as Medicine

  • Tracking the Money That’s Legalizing Marijuana and Why It Matters documents state-by-state financial data, exposing the groups and the amount of money used either to fund or oppose ballot initiatives legalizing medical or recreational marijuana in 16 U.S. states.
  •  NFIA report reveals three billionaires—George Soros, Peter Lewis and John Sperling—who contributed 80 percent of the money to medicalize marijuana through state ballot initiatives during a 13-year period, with the strategy to use medical marijuana as a runway to legalized recreational pot.
  •  Report shows how billionaires and marijuana legalizers manipulated the ballot initiative process, outspent the people who opposed marijuana and convinced voters that marijuana is medicine, even while most of the scientific and medical communities say marijuana is not medicine and should not be legal.
  •  Children in Colorado treated with unregulated cannabis oil have had severe dystonic reactions, other movement disorders, developmental regression, intractable vomiting and worsening seizures.
  •  A medical marijuana industry has emerged to join the billionaires in financing initiatives to legalize recreational pot.

Atlanta, Ga. (March 14, 2017)—A new report by National Families in Action (NFIA) uncovers and documents how three billionaires, who favour legal recreational marijuana, manipulated the ballot initiative process in 16 U.S. states for more than a decade, convincing voters to legalize medical marijuana. NFIA is an Atlanta-based nonprofit organization, founded in 1977, that has been helping parents prevent children from using alcohol, tobacco, and other drugs. NFIA researched and issued the paper to mark its 40th anniversary.

The NFIA study, Tracking the Money That’s Legalizing Marijuana and Why It Matters, exposes, for the first time, the money trail behind the marijuana legalization effort during a 13-year period. The report lays bare the strategy to use medical marijuana as a runway to legalized recreational pot, describing how financier George Soros, insurance magnate Peter Lewis, and for-profit education baron John Sperling (and groups they and their families fund) systematically chipped away at resistance to marijuana while denying that full legalization was their goal.

The report documents state-by-state financial data, identifying the groups and the amount of money used either to fund or oppose ballot initiatives legalizing medical or recreational marijuana in 16 states. The paper unearths how legalizers fleeced voters and outspent—sometimes by hundreds of times—the people who opposed marijuana.

Tracking the Money That’s Legalizing Marijuana and Why It Matters illustrates that legalizers lied about the health benefits of marijuana, preyed on the hopes of sick people, flouted scientific evidence and advice from the medical community and gutted consumer protections against unsafe, ineffective drugs. And, it proves that once the billionaires achieved their goal of legalizing recreational marijuana (in Colorado and Washington in 2012), they virtually stopped financing medical pot ballot initiatives and switched to financing recreational pot. In 2014 and 2016, they donated $44 million to legalize recreational pot in Alaska, Oregon, California, Arizona, Nevada, Massachusetts and Maine. Only Arizona defeated the onslaught (for recreational marijuana).

Unravelling the Legalization Strategy: Behind the Curtain In 1992, financier George Soros contributed an estimated $15 million to several groups he advised to stop advocating for outright legalization and start working toward what he called more winnable issues such as medical marijuana.

At a press conference in 1993, Richard Cowen, then-director of the National Organization for the Reform of Marijuana Laws, said, “The key to it [full legalization] is medical access. Because, once you have hundreds of thousands of people using marijuana medically, under medical supervision, the whole scam is going to be blown. The consensus here is that medical marijuana is our strongest suit. It is our point of leverage which will move us toward the legalization of marijuana for personal use.”

Between 1996 and 2009, Soros, Lewis and Sperling contributed 80 percent of the money to medicalize marijuana through state ballot initiatives. Their financial contributions, exceeding $15.7 million (of the $19.5 million total funding), enabled their groups to lie to voters in advertising campaigns, cover up marijuana’s harmful effects, and portray pot as medicine—leading people to believe that the drug is safe and should be legal for any use.

Today, polls show how successful the billionaires and their money have been. In 28 U.S. states and the District of Columbia, voters and, later, legislators have shown they believe marijuana is medicine, even though most of the scientific and medical communities say marijuana is not medicine and should not be legal. While the most recent report, issued by the National Academies of Sciences (NAS), finds that marijuana may alleviate certain kinds of pain, it also finds there is no rigorous, medically acceptable documentation that marijuana is effective in treating any other illness. At the same time, science offers irrefutable evidence that marijuana is addictive, harmful and can hinder brain development in adolescents. At the distribution level, there are no controls on the people who sell to consumers. Budtenders (marijuana bartenders) have no medical or pharmaceutical training or qualifications.

One tactic used by legalizers was taking advantage of voter empathy for sick people, along with the confusion about science and how the FDA approves drugs. A positive finding in a test tube or petri dish is merely a first step in a long, rigorous process leading to scientific consensus about the efficacy of a drug. Scientific proof comes after randomized, controlled clinical trials, and many drugs with promising early stage results never make it through the complex sets of hurdles that prove efficacy and safety. But marijuana legalizers use early promise and thin science to persuade and manipulate empathetic legislators and voters into buying the spin that marijuana is a cure-all.

People who are sick already have access to two FDA-approved drugs, Dronabinol and Nabilone, that are not marijuana, but contain identical copies of some of the components of marijuana. These drugs, available as pills, effectively treat chemotherapy-induced nausea and vomiting and AIDS wasting. The NAS reviewed 10,700 abstracts of marijuana studies conducted since 1999, finding that these two oral drugs are effective in adults for the conditions described above. An extract containing two marijuana chemicals that is approved in other countries, reduces spasticity caused by multiple sclerosis. But there is no evidence that marijuana treats other diseases, including epilepsy and most of the other medical conditions the states have legalized marijuana to treat. These conditions range from Amyotrophic lateral sclerosis (ALS) and Crohn’s disease to Hepatitis-C, post-traumatic stress disorder (PTSD) and even sickle cell disease.

Not So Fast – What about the Regulations?

Legalizers also have convinced Americans that unregulated cannabidiol, a marijuana component branded as cannabis oil, CBD, or Charlotte’s Web, cures intractable seizures in children with epilepsy, and polls show some 90 percent of Americans want medical marijuana legalized, particularly for these sick children. In Colorado, the American Epilepsy Society reports that children with epilepsy are receiving unregulated, highly variable artisanal preparations of cannabis oil recommended, in most cases, by doctors with no training in paediatrics, neurology or epilepsy. Young patients have had severe dystonic reactions and other movement disorders, developmental regression, intractable vomiting and worsening seizures that can be so severe that their physicians have to put the child into a coma to get the seizures to stop. Because of these dangerous side effects, not one paediatric neurologist in Colorado, where unregulated cannabidiol is legal, recommends it for these children.

Dr. Sanjay Gupta further clouded the issue when he produced Weed in 2013, a three-part documentary series for CNN on marijuana as medicine. In all three programs, Dr. Gupta promoted CBD oil, the kind the American Epilepsy Society calls artisanal. This is because not one CBD product sold in legal states has been purified to Food and Drug Administration (FDA) standards, tested, or proven safe and effective. The U.S. Congress and the FDA developed rigid processes to review drugs and prevent medical tragedies such as birth defects caused by thalidomide. These processes have facilitated the greatest advances in medicine in history.

“By end-running the FDA, three billionaires have been willing to wreck the drug approval process that has protected Americans from unsafe, ineffective drugs for more than a century,” said Sue Rusche, president and CEO of National Families in Action and author of the report. “Unsubstantiated claims for the curative powers of marijuana abound.” No one can be sure of the purity, content, side effects or potential of medical marijuana to cause cancer or any other disease. When people get sick from medical marijuana, there are no uniform mechanisms to recall products causing the harm. Some pot medicines contain no active ingredients. Others contain contaminants. “Sick people, especially children, suffer while marijuana medicine men make money at their expense,” added Ms. Rusche.

Marijuana Industry – Taking a Page from the Tobacco Industry The paper draws a parallel between the marijuana and tobacco industries, both built with the knowledge that a certain percentage of users will become addicted and guaranteed lifetime customers. Like tobacco, legalized marijuana will produce an unprecedented array of new health, safety and financial consequences to Americans and their children.

“Americans learned the hard way about the tragic effects of tobacco and the deceptive practices of the tobacco industry. Making another addictive drug legal unleashes a commercial business that is unable to resist the opportunity to make billions of dollars on the back of human suffering, unattained life goals, disease, and death,” said Ms. Rusche. “If people genuinely understood that marijuana can cause cognitive, safety and mental health problems, is addictive, and that addiction rates may be three times higher than reported, neither voters nor legislators would legalize pot.” NDPA recommends readers to read the whole report Tracking the Money That’s Legalizing Marijuana and Why It Matters

Source: www.nationalfamilies.org. 2017

· Trials on mice found THC – which causes the ‘high’ in weed, can induce seizures

· The same was shown for JWH-018 – the main part of the synthetic cannabis spice

· Japanese researchers have described their findings are being ‘quite important’

· Skunk, made mostly of THC, dominates the illegal British market of marijuana

Smoking super-strength cannabis or spice may trigger life-threatening seizures, researchers have warned.

Trials on mice showed seizures can be induced by both THC – which causes the ‘high’ in marijuana, and JWH-018 – the main component of spice. The rodents also suffered from a shortness of breath and impaired walking after being given both compounds, the scientists discovered.

Japanese researchers warned the results should act as a wake-up call, given how widely high-potency and synthetic weed is used.

The findings contradicts pro-cannabis campaigners who have long argued that cannabis can help to tackle seizures and highlighted research which shows weed can prevent and control seizures in epileptic patients.

However, lead researcher Dr Olga Malyshevskaya, based at the University of Tsukuba, said the latest findings show cannabis is not a soft drug and warned of its dangers.

She said: ‘Our study is quite important. Unaware of the particularly severe effect by those cannabinoids, people see marijuana as a soft drug, without dangerous health effects.’

She added: ‘It is critically important for health-care professionals and policy makers to be aware of the serious adverse effects, as shown in this report. Clinicians in the emergency departments should always suspect seizure activity in patients who have a history of cannabinoid intoxication.

WHAT IS THC?

THC is found in all forms of cannabis, but is abundant in skunk – a super-strength form of the drug that dominates Britain’s illegal market.

Some 80 per cent of what is available on the streets is believed to be skunk, which is created by growers aiming to make the most potent strain of the drug possible in order to maximise their profits.

They remove high amounts of CBD from the plant, allowing the modified herb to contain only THC. It is unsure how much THC was in the strain of cannabis used in the new study.

Over the years, a host of previous research has pointed to a link between the popular recreational drug and mental health conditions. Last October, University College London researchers found that skunk may be twice as addictive as normal strains of cannabis.

Similar health concerns have been raised about synthetic cannabis spice, which can slump users and turn them into ‘zombies’.

It was previously known as a legal high before it was banned last year following a surge in its use. Now it has reached epidemic levels in prison.

‘The number of clinical cases involving marijuana intoxication has been steadily increasing due to increase in cannabis potency over the last two decades.’

What do other experts think?

Ian Hamilton, a cannabis researcher at York University, cautioned the results, which are published in Scientific Reports.

He told MailOnline: ‘We don’t know if people who use cannabis are using something as potent as this.’ For the study, researchers measured the brain activity of the mice after giving them both compounds and recorded them.

Research that claims to show cannabis can control seizures

The findings contradict a body of research which shows weed can prevent and control seizures in epileptic patients. Campaigners have long argued that cannabis has the opposite effect to the new findings and can help to tackle seizures.

Researchers have previously suggested that CBD – the other compound in cannabis which produces no ‘high’, binds to a receptor in the brain that calms down the electrical activity in the brain which causes a seizure.

First Briton to be prescribed liquid cannabis oil on the NHS

Their case was strengthened when an 11-year-old on the brink of death from a severe form of epilepsy made an ‘incredible’ recovery from taking marijuana.

Billy Caldwell, from Castlederg, Northern Ireland, made headlines in April when he became the first Briton to be prescribed such a drug on the NHS.

And 10 months since he was first given the liquid cannabis oil, he hasn’t had any seizures. He used to suffer up to 100 a day.

THE MAN WHO SUFFERS SEIZURES FROM SYNTHETIC CANNABIS

The news comes just a week after DailyMail.com reported on a disturbing video which shows a man from Des Moines, Iowa, having a seizure as an effect of years smoking synthetic marijuana.

Coby O’Brien-Emerick, 27, has experienced chronic seizures every three months for the past five years, putting him in the hospital for weeks on end.

In the video uploaded in December, Coby is seen on the floor convulsing for about nine minutes while paramedics are being called.

The father-of-two told Dailymail.com he asked for his seizure to be recorded in order to understand the severity of it.

The video was posted to YouTube by his mother-in-law to warn others about the dangerous effects of smoking synthetic marijuana .

Source: http://www.dailymail.co.uk/health/article-4917100/Smoking-super-strength-cannabis-trigger-seizures.html 26 Sept. 2017

Draft rules are unlikely to contain an exemption to state law barring smoking in public places, so pot would have to be consumed through edibles or tincture.

Maine may be the first state in the country to license marijuana social clubs, but the pot could not be smoked in the clubs and would have to be consumed in another manner.

The legislation to regulate adult-use marijuana under consideration in Augusta now would push club licensing off until at least June 2019, about a year after Maine’s first retail stores are likely to open. Although not thrilled with the delay, most legalization advocates say they are just happy that club licensing was not stripped out of the bill, which is a legislative rewrite of last November’s successful citizen initiative.

The bill does not expressly prohibit smoking in the clubs, but it also doesn’t carve out an exemption to the state’s no-smoking law, which bans smoking of any kind, including vaping, in public places such as bars and restaurants. That means the clubs would be limited to the sale of pot edibles or tinctures that patrons would have to use on site, said state Sen. Roger Katz, R-Augusta, co-chairman of the Legislature’s Committee on Marijuana Legalization Implementation.

“The committee was divided on this issue,” Katz said. “Some of us, including myself, did not want to be the first state to experiment with social clubs because of the public safety concerns. Others said it was going to happen anyway, better we recognize it and appropriately license and regulate them, which is what voters wanted. But we had consensus on keeping our smoking ban intact.”

NO POT SMOKING-LAW EXEMPTION

Maine law currently allows smoking in cigar bars, but Katz said a majority of committee members didn’t want to add a smoking law exemption for marijuana. The bill is still in draft form, however, so it could undergo many changes before it is sent to the full Legislature for a vote next month. A public hearing on the bill is scheduled to begin at 9 a.m. Tuesday at the State House in Augusta.

Advocates in Maine are pleased that the bill would allow club patrons to buy and use marijuana in the same location, but they argue that the 2019 licensing date is too late. They want cannabis social clubs to have the same rights as alcohol and tobacco clubs. A city like Portland should be able to license a marijuana club with a rooftop patio that would allow outdoor smoking, said advocate David Boyer.

“We have social clubs for alcohol, and they are called bars,” said Boyer, director of the Maine chapter of the Marijuana Policy Project, one of the groups that helped pass the Marijuana Legalization Act last fall. “Bars can have outside smoking patios. And cigar clubs, they certainly allow smoking. Marijuana is safer than either of those substances.”

Boyer’s organization is considering a petition drive in Portland to establish local licensing rules for social clubs that would be ready to implement in order to speed up the process once the clubs are approved. That might not be necessary, however, because city officials are thinking along the same lines and are already planning a fact-finding trip to Denver.

But legalization opponents say social clubs are just one of the reasons they lobbied against the ballot question last year. The leader of Mainers Protecting Our Youth and Communities, Scott Gagnon, has said social clubs would put more impaired drivers on

Maine roads. Since no state has yet licensed social clubs, there are no data available on whether they would lead to more traffic accidents or fatalities.

IMPACT ON ROAD SAFETY UNCLEAR

Data on the impact of legalization on traffic safety are mixed.

Like many other states, Maine has had its share of underground marijuana-friendly clubs, and certain parks and beaches are popular spots to use marijuana with different degrees of discretion. The adult-use law adopted last fall allows adults to grow six plants on their own property or someone else’s, with permission, and have up to 2½ ounces of marijuana in their possession for personal use.

Current law bans public cultivation or consumption, which doesn’t give the 36 million people who visit Maine each year a place to use any pot that they might buy when here, because most hotels ban smoking inside rooms. Club advocates have said pot lounges would give tourists a legal place to use the pot they buy here and keep them out of the parks and off the beaches.

But a review of other states’ marijuana laws and regulations reveals that marijuana clubs remain uncharted territory in the national landscape. Even in Colorado, which was the first state in the nation to legalize recreational marijuana, government officials have been reluctant to license pot clubs, worried that it would invite federal authorities to crack down on a drug that is still illegal under federal law.

Oregon does not allow pot social clubs. Alaska and California are considering whether to license them. California, Nevada and Colorado laws do not prohibit clubs, so local governments could agree to grant licenses. So far, only Colorado City has any licensed social clubs, where consumers can use pot they bring with them – but even those are under order to shut down by 2023.

Denver adopted a pot social club pilot program and announced it was ready to begin accepting applications last month, but so far no one has applied. Would-be club operators say the rules are too restrictive, partly because they ban consumption at places that sell marijuana, essentially making clubs a bring-your-own venue, and require clubs to be twice as far away from schools or playgrounds as bars.

Massachusetts law allows social clubs in local municipalities, but the newly appointed Cannabis Control Commission will likely take up that issue while it writes state regulations. A Denver-based party bus service, Loopr, which bills itself as a mobile cannabis lounge, is targeting Boston for expansion into New England next year, as well as having franchises in California and Nevada.

ADVICE: DON’T BE THE GUINEA PIG

“I always advise clients you don’t want to be the first at something,” said Andrew Freedman, former director of marijuana coordination for Colorado who now works as a marijuana consultant. “It’s better to see what other states have done to see what works, and what doesn’t, with marijuana. There’s a lot of public health and safety on the line, and the federal authorities are always watching. Freedman’s firm is now taking on state clients to advise them on how to set up their adult-use markets, and would like to find work in Maine.

Source: http://www.pressherald.com/2017/09/25/maines-marijuana-social-clubs-likely-to-be-no-smoking-venues/

A recent review published in the scientific journal Addiction has shed much needed light on an important but rarely discussed condition associated with Substance Use Disorders. Advanced dental disease, including tooth decay and periodontal conditions, are common comorbid conditions among persons with Substance Use Disorders.

To determine the prevalence, investigators conducted an exhaustive systematic search for studies from the past 35 years germane to oral health among substance abusers. Medline, PsycInfo, Ovid, Google Scholar, Embase and article bibliographies were reviewed and analyzed. The results were compared with the general population of non-substance using controls. Parameters of oral health were defined in terms of tooth decay and periodontal disease by comparing the percent of decayed, missing and filled teeth (DMFT) or surfaces (DMFS) and probing gum pocket depth. In total, this review culled the results of 28 studies yielding comparative data on 4,086 dental patients with substance use disorder and 28,031 controls.

Drugs and Dental Disease

Drug abuse affects oral health via direct physiological routes including dry mouth, craving and consumption of sugary sweets and processed carbohydrate snacks (munchies), and most recently processed cannabis sweets, such as gummy bears, candy, cookies and of course…brownies. Cocaine, methamphetamine and other drugs of abuse may interfere with the blood supply to teeth and gums. Teeth clenching and grinding (bruxism), is associated with the chronic use of stimulants and Ecstasy as well as anxiety and depression, which are common comorbidities of Substance Use Disorders. Chemical erosion resulting from excessive use of alcohol, coffee or from applying highly acid drugs such as cocaine to one’s teeth and gums are causative of oral disease. Lastly, given the choice between drug self-administration and flossing or brushing regularly, abusers and addicts pick drugs of abuse.

Why Does This Matter?

As we age, oral health has increasingly significant consequences on our quality of life and overall health. At its best, persons with serious dental and periodontal disease suffer difficulty masticating and observable aesthetic problems that negatively impact self-esteem. At its worse, dental and oral disease cause chronic inflammation and bacteremia, which are risk factors for heart disease, stroke, diabetes and compromised respiratory function. The findings from this study are similar to the outcomes associated with severe mental illness and eating disorders.

The addition of 2.8 million new drug users each year is unsustainable for our current healthcare system. It is difficult to get many users primary medical or addiction care. It is almost impossible to get Substance Use Disorders patients to the dentist. Health disparities and access to care are ongoing public health crises. We will either need a lot more doctors and dentists or a lot fewer drug addicts.

In the clinical setting, we can make a difference. Clinicians who evaluate and treat people with substance use disorders should make certain to include a mouth, gum, and dental history and oral exam. We should routinely screen for oral diseases, arrange for dental care as needed, and educate patients of the oral health risks associated with Substance Use Disorders, dry mouth and cravings for foods with high sugar content.

Source: https://www.rivermendhealth.com/resources/dental-disease-common-serious-seldom-discussed-comorbidity-sud/ September 2017

Drug trafficking is now the most murderous criminal activity in American history. Overdose deaths from illegal drugs passed 50,000 in 2015 — many times the number of Americans killed by all Islamic terrorists over almost 20 years. Yet stopping the skyrocketing body count will require overcoming a pervasive misunderstanding of how drug abuse and addiction are caused.

Blaming the victim has created confusion and policy failure. No one starts using drugs intending to become an addict. While addiction may seem like slow-motion suicide, most addicts do not want to die — the poison hooks them, taking over their life. Media reports of addiction are mixed with entertainment and social media that present drug use as commonplace. More and more Americans are drawn to the flame, many introduced to substance abuse by a friend or family member. “Just say no” is dead. Yes, encouraging young people not to use drugs can save individual lives, but personal morality is not the right battleground.

There are multiple factors that may be contributing to this crisis. Does expanding supply trigger drug experimentation? Does human biology simply include a dangerous susceptibly to runaway addiction? Or is cultural confusion about freedom and self-destruction enabling and normalizing drug addiction? All these factors (and possibly more) likely play a part. But what causes an epidemic is the addictive poison itself, spread in sufficient quantities. Ultimately, America’s addiction catastrophe is properly understood as a mass poisoning.

As a result, cutting the drug supply — and only cutting supply — will reduce deaths and addiction. The evidence for this conclusion is manifest; ignoring it will cost countless more lives.

Curtailing Supply

There was no demand for crack before it was created and distributed by Colombian traffickers. There was no demand for meth before it was created by criminal gangs and then “cooked” by users. Similarly, there was no massive abuse of prescription opioids until they were irresponsibly marketed by some manufacturers and prescribed by physicians contrary to sound medical practice.

The increase in heroin and fentanyl use, addiction, and deaths followed the increase in the supply from Mexico and China. Conversely, during the George W. Bush Administration, when the supply of cocaine, crack, and meth began declining, use declined. Now, as cocaine production in Colombia has grown again, use and overdose deaths are climbing. Finally, the leveling trend in the abuse of prescription opioids has followed enforcement actions against pill mills and criminal physicians — that is, it follows an apparent reduction in supply. Americans have long accepted the claim that it is impossible to stop drug trafficking, even in the face of extensive evidence to the contrary. Anti-terrorism efforts must stop just a few dedicated individuals. This is a tough problem that Americans see solved every day. Yet the poisoning of millions is supposedly unstoppable. It isn’t.

Moreover, misunderstanding the cause of drug epidemics has shifted the policy debate away from the right goals: reducing the supply of drugs and returning addicts to sobriety. With deaths at historic levels, some still maintain that drug use is a right or otherwise not worth the cost of controlling. This harm reduction position is at odds with both supply control and all forms of prevention education — and increasingly at odds with treatment understood as having the goal of abstinence.

Many drug policy progressives now insist on medically supervised addiction. Such medication assisted treatment (MAT) amounts to government-supervised facilities for drug use (injection sites) or even government-supplied drugs for the addicted. The model here is the Netherlands, where endless, government-supported drug use is treated as a means of treating addiction. These addicts continue to be victimized by their own country, fostering a separate and profoundly dysfunctional underclass.

In the face of expanding supply, prevention and treatment efforts cannot be strategic — they can save individual lives, but new lives will be put at risk. This is merely squeezing an uncontained balloon. Moreover, if supply is reduced significantly, use and addiction will necessarily fall without respect to prevention and treatment efforts. The evidence of almost 50 years indicates that prevention and treatment efforts only contribute to strategic results when supply is reduced.

Prevention and treatment save lives, but their strategic effect is overwhelmed if supply and trafficking are not curtailed.

Policy proposals placing emphasis on reviving drug overdose victims mistake cause and effect. In the case of opioid addiction, the cause is the opioids themselves and increasingly, fentanyl. Revived addicts are still victims, and, sadly, many treated for opioid addiction will relapse in the face of burgeoning supply. Fentanyl and its variants are now driving the rapid rise in opioid deaths and drug overdoses in general. Information, albeit inadequate, suggests China is the source for these substances and the precursors to produce them. It seems there is no large-scale legitimate use for these chemicals outside of what is supposed to be controlled production for limited medical use — thus, industrial diversion is not a primary issue. Unfortunately, however, this means U.S. officials cannot attack fentanyl directly, but only via Chinese enforcement action.

China is likely to be sensitive to sustained pressure by authoritative American voices, whether from federal officials or prominent private individuals. America should ramp up this pressure soon. If executive branch officials cannot lead the charge, individuals from outside the executive, including members of Congress, should take the lead.

The Chinese are likely to act only in response to threats to their political or economic interests. Spurring them to act may require frequent confrontations over their performance in stopping fentanyl trafficking to the U.S. and Mexico. But sustained, genuine pressure works.

It is also possible that fentanyl and precursors are being trafficked from other Asian countries. Hence further — and swift — investigation is needed.

Bolstering Intelligence Resources

It is reasonable to anticipate that traffickers will seek to move production in response to pressure. If that happens, other Asian nations can be pressured by a range of escalating sanctions. Identification, especially public charging of foreign criminals, can be particularly helpful in disrupting trafficking operations, along with attacks on criminal funds and individuals through U.S. law.

An attack of sufficient power to collapse trafficking networks requires detailed intelligence. Such intelligence is also needed to prod foreign governments to act within their authority. Greater intelligence resources are also crucial for attacking trafficker finance, corruption operations, and measuring policy effectiveness. Attacking networks and responding to the drug epidemic requires comprehensive, real-time data. This data — from foreign intelligence services, domestic law enforcement agencies, and public health reports — should be fused into a strategic whole.

Fortunately, American intelligence has developed tools to attack such networked terrorist threats. At over 50,000 overdose deaths a year, the mass poisoning of drug trafficking is the most profound attack on America today. It is time to fully unleash intelligence tools on trafficking networks.

Without adequate intelligence, the magnitude of trafficking on the internet and “dark web” is unknown. Available information suggests it is significant, however. Federal drug enforcement has generally made electronic investigations a low priority, rejecting proposals to disrupt such markets by means of false sites, service denials, and cross-referencing data from multiple sources. All national security capacities are not yet deployed against opioid trafficking on the internet; this should change immediately. Past efforts to mount internet attacks by federal drug enforcement agencies have been crippled by ignorance, lack of experience, lack of vision, and complacency. The primary strategic goal should not just be to make future cases, but permanent market disruption; make it difficult to use the internet for trafficking by destroying the ability of buyers to connect with sellers.

Even the incomplete information on the opioid epidemic suggests that enforcement actions against pill mills and criminal physicians have reduced addiction and death driven by U.S. pharmaceutical sources. This has been a “supply control” success. Nonetheless, there is evidence of lower, but continued diversion. The pharmaceutical industry, the health insurance industry, and the federal government (the largest single health-care payer) all have information that should be brought together to identify and stop criminal diversion. The key point should be to focus attention on the biggest threat and its biggest components. There are regular reports of misuse of federal health-care funds to support addiction; some reports suggest areas where such practices are concentrated, which may serve as a starting point for enforcement actions.

Disrupting Networks Colombia is now back to producing more cocaine than it did prior to the dramatic drop in coca cultivation through Plan Colombia, which was largely due to the cooperation of former President Alvaro Uribe. Aside from a corresponding rise in cocaine overdose deaths, there are now reports of deaths resulting from cocaine-fentanyl mixtures. This deadly combination was seen about 10 years ago and may now be poised to cause harm on a greater scale. Much more fentanyl is available to Mexican traffickers carrying opioids and cocaine into the U.S. The Obama administration downplayed drug control in Colombia to pursue other goals. Colombian institutions are, again, put at risk by narcoterrorism. The previous security partnership needs reinvigoration, but the U.S. should make clear that the current trends are unacceptable for an ally and trading partner. A first step might be to have a government official or prominent private citizen warn the Colombian president that “if he doesn’t stop sending the cocaine, perhaps it is time to ask him to stop sending the coffee and the flowers.” Fortunately, former-president Uribe remains politically active and he knows how to attack the cocaine problem — Colombians would be wise to give him the job.

Contrary to the widespread belief that prescription diversion is driving the opioid crisis, available evidence indicates that most opioids and other illegal are produced outside the U.S. Further, these drugs seem to be arriving from Mexico. It is likely that most of them pass within six feet of a uniformed federal officer at our southern border. This is an unacceptable failure. Additional personnel will be useful, but the most important missing element is access to intelligence about trafficker operations. Enforcement agencies need to “see” into Mexico, and they need to see the structure of foreign and domestic trafficking networks.

Drug enforcement agencies and prosecutors need to treat individual cases as a means of network disruption, not as ends in themselves. In fact, it is likely that many smaller cases involving lesser charges that can be brought quickly will damage street-level trafficking networks more effectively than larger cases requiring longer investigations. In short, enforcement efforts need to become urgent and strategic.

Moreover, traffickers deserve stiff prison sentences. Such sentences are important leverage for turning traffickers against each other. Prison capacity for these death merchants must be made available to save lives. Enforcement pressure needs to be scaled to the threat.

Overall, drug enforcement management is insufficiently threat-based and seldom shifts resources rapidly to the greatest threats. While drug trafficking is killing more Americans than all other criminal activity combined, drug enforcement does not receive resources remotely proportional to the threat. The criminal-justice system is merely trying (and failing) to cope with the drug threat. It must come to see its mission as systematically destroying the threat — and plan, budget, and staff accordingly.

A Counter-Drug Strategy

An effective counter-drug strategy must attack at three points: source, distribution, and retail. If any one point of attack is particularly effective, it will substantially reduce use. It is probable, however, that the different points of attack will be effective in different degrees, while results will be cumulative and reinforcing.

At the retail level of street sales and use, the targets are whole communities, large geographic areas. Local and state efforts will be most important because there are insufficient federal resources to create the magnitude of the response required at the retail level. Local and state elements can be “enlisted” in a more unified national effort. That means encouraging and offering supplementary, strategic support with national personnel and resources.

Nevertheless, it may be critical to begin with willing state and local partners — those who commit their personnel and resources to the new strategy. These initial sites will also refine the elements of the strategy and demonstrate the effectiveness of more controversial components. Sites should be in priority areas and on as wide a scale as circumstances permit, but they should also be understood as points from which localized effort will flow outward — as ink spots on paper. Taking back individual communities in this way is an application of counterinsurgency concepts — it is also an established means of fighting epidemics.

At the retail level, the dealer and user are the center of gravity. Street-level enforcement needs to respond to opioid distribution as an immediate threat to life. Every sale can bring an overdose and every overdose can result in death. Each dealer is more like an active shooter than a house thief. Yet police response is frequently more focused on victim than on victimizer. The low-level dealer is also a low priority for enforcement personnel and prosecutors. This misguided policy is feeding the epidemic at the local level.

Accordingly, street-level enforcement should be reconceived in two ways. First, much greater urgency should be given to finding and incapacitating the dealer. Second, arresting users should be seen as a public health measure to screen for and treat addiction, as with the successful drug court model. Drug courts and diversion programs are already a major source of treatment admissions in the U.S. But this has been understood as a means of reducing the burden on the criminal-justice system. It should be seen as a necessary means of getting addicts who are in denial (as the vast majority are) into treatment and keeping them there through detoxification and stable sobriety. Street-level enforcement should be targeted to collapse dealer networks and should be tuned to become an intake channel for treatment.

All this will mean more arrests and more resources devoted to creating appropriate responses for users and dealers after arrest. Occasional, non-addicted users have a much lower probability of arrest at the point of drug sales because their purchases are infrequent. The risk to addicts is greater because they commonly need multiple doses per day. Thus, the normal pressure of street-level enforcement will tend to involve the larger dealers and the heavier users. Arrest and referral to treatment will save the lives of the addicted and even the arrest and warning of occasional users could be a potentially life-saving deterrent.

Such enforcement effort needs to be targeted, however. The obvious way to locate addicts and their dealers is to follow the reports of overdose victims. These reports provide a painful — but clear — geographic map of the epidemic. That map should be the basis for identifying priority areas nationally.

Currently, national information on overdose deaths lags by more than a year. This is unacceptable, and public health officials should be held accountable for creating a local, state, and national, real-time map of the epidemic. Preventing death means stopping traffickers and bringing effective outreach to the addicted in real time.

Finally, while attacking the source and border interdiction take the form of “outside-in” efforts, street enforcement and treatment involves an “inside-out” movement. Is this possible? Can individual communities make progress in the absence of full national success against the drug supply? Can a neighborhood-by-neighborhood strategy work?

Certainly, there is a risk of the epidemic moving back into improved areas from nearby trafficker enclaves. But, in fact, there are many law enforcement examples demonstrating that crime and drug trafficking is displaceable and containable with sustained, effective effort. The pace of the attack matters, and must run ahead of criminal replacement efforts. Local law enforcement agencies successfully contain certain crimes within specific geographic areas, and respond aggressively if criminals overstep boundaries. As in other matters, overwhelming the problem requires capable leadership with the authority, resources, and determination to prevail. For each part of the strategy above, it is important that one individual receive overall responsibility and that this individual understand that they will be removed in the absence of rapid progress. There is no accountability if there is no individual accountability.

The future of addiction in America rests on whether the supply of addictive drugs is dramatically reduced. The drug policy of the Trump administration will determine whether use and addiction are diminished or if they are more deeply embedded in American life — further expanding the underclass of addicted individuals living in misery and dying too young.

John P. Walters, chief operating officer of the Hudson Institute, was Director of National Drug Control Policy (2001–09).

Source: http://www.realclearpolicy.com/articles/2017/09/21/stopping_the_drug_epidemic_110362.html

Comment from Carla Lowe in the USA:

Hello from California,

A most informative article on the opioid epidemic from our friend John Walters. But I wonder how he would justify not addressing marijuana as a key link to this problem.

Perhaps he, like others far from California, is not aware of our 50,000 illegal marijuana grows, a 35 billion dollar business supplying 60% of the nation’s pot. And this is all in the name of so-called “medical” marijuana.

This situation will become significantly worse after January 1st when marijuana will be available just for fun for those over 21. Only Fools would think that kids’ use won’t rise in our formally golden state, now tragically turning green.

Please help us call on President Trump to enforce federal drug laws. It is absolutely our only hope in turning back this madness.

Carla Lowe CALMca.org

Comment from Dr. Stuart Reece in Australia

Yes John. The above is correct but only a partial analysis. Addiction is often based on the gateway drugs cannabis, alcohol and tobacco. Not only is this addictive basis not being addressed by current policies and practice but it is actively being sponsored by many US state Governments in the extremely false belief that reimbursement through taxation with compensate the community for the virtually endless destruction wrecked by drugs at all levels. Up till now the Feds have not addressed this issue either.

Worse still is what is being done to the next generation. It is not rocket science to observe that the children of these addicted patients are mostly not normal. This is very different to the rest of the community. Not only so but cannabis almost certainly underlies the international “gastroschisis epidemic” (where babies are born with their bowels hanging outside of their body) which no one is talking about, and is commonest in the youngest parents – because they smoke the most weed.

If we don’t start telling the truth about addiction in its totality the web of lies will engulf and enslave us all. The hardest hit will be the children and the poor. And, just as has happened in every single community across the globe in developed and developing nations, social decay and distress will become rampant and profligate.

Freedom begins with the truth – and showing a way out of our seductive mess – and breaking the spell of those who cannot wait to cash in on the collapse of the West.

Prince William was last night branded ‘naive’ for raising the contentious issue of whether drugs should be legalised with a group of former addicts.

His invitation to discuss the highly controversial topic will give ‘grist to the mill’ of the ‘powerful’ pro-legalisation lobby, an expert warned.

The future king, who in recent weeks has embarked on a new role as a full-time working royal after quitting his job as an air ambulance pilot, spoke out on a visit to an addiction charity on Tuesday.

William admitted the issue of legalising drugs was a ‘massive’ question as he spoke to the former addicts, although he steered clear of voicing an opinion himself.

However, Kathy Gyngell, a research fellow at think-tank the Centre for Policy Studies, said the prince’s question was ‘well-meaning but naive’ and he risked giving succour to those campaigning for a relaxation in the law.

Other experts warned that making it legal to use dangerous substances would send out the wrong message and harm vulnerable people.

The Home Office also issued a blunt statement saying it had no plans to decriminalise drugs because of ‘substantial’ evidence showing they damaged both physical and mental health.

William raised the issue while visiting the Spitalfields Crypt Trust in east London which works with people battling substance abuse.

He said to the former addicts: ‘Can I ask you a very massive question – it’s a big one. ‘There’s obviously a lot of pressure growing on areas about legalising drugs. What are your individual opinions on that?’

Heather Blackburn, 49, from Hackney, replied: ‘I think that it would be a good idea but the money is kind of wasted on drug laws, that put people in prison… You get punished – which is not going to stop anyone taking drugs.’

But Miss Gyngell said William’s question suggested he failed to grasp that what addicts need is earlier intervention from the authorities, not greater freedom.

She said: ‘Had Prince William asked whether legalising drugs would help addicts quit their addiction, he might have received a different reply.

‘Addicts in recovery that I have spoken to say that enabling supply, making drugs cheaper and normalising general use by the removal of sanctions, is the last thing they or we need.

‘Their turning point often was arrest and police pushing them, not into prison, but into treatment.

‘But a propaganda battle has raged in the UK for 25 years or more for legalising drugs, backed by powerful and well-financed legalisation lobbies.

‘The prince’s well-meaning but naive intervention gives grist to their mill.’

Miss Gyngell told The Guardian the debate over how to combat the country’s drugs problem should centre around more prohibition, not less.

Dr Marta Di Forti, a consultant psychiatrist at King’s College London, said: ‘My concern about asking drug addicts for their views is that drug addicts have views related to their experiences.

‘The harm that is reported to be done by cannabis does not come from addiction but among people who develop mental illnesses.’

Norman Wells, of the Family Education Trust, added: ‘Laws prohibiting the sale and use of certain drugs are in place for good reason.

‘To decriminalise drugs would send out all the wrong messages – especially to vulnerable young people.’

Professor Neil McKeganey, director of the Centre for Drug Misuse Research in Glasgow, said asking people who have abused drugs did not give a rounded view of the situation, when the laws were also there to protect the largely law-abiding general public.

Sources close to the prince stressed that he was not attempting to intervene in the issue or express a view, but trying understand the ‘very complicated issues’ around the legalisation debate.

Source: http://www.dailymail.co.uk/news/article-4904944/Prince-William-branded-naive-legalising-drugs-remark.html 21st Sept. 2017

Filed under: Social Affairs :

Consumption of alcohol, tobacco and illegal psychoactive substances, mainly cannabis, have increased in the last five years in Portugal, according to a study by the Intervention Service for Addictive Behaviours and Dependencies (SICAD).

“We have seen a rise in the prevalence of alcohol and tobacco consumption and of every illicit psychoactive substance (essentially affected by the weight of cannabis use in the population aged 15-74) between 2012 and 2016/17, according to the 4thNational Survey on the Use of Psychoactive Substances in the General Population, Portugal 2016/17.

The study focused on the use of legal psychoactive substance (alcohol, tobacco, sedatives, tranquilizers and/or hypnotics, and anabolic steroids), and illegal drugs (cannabis, ecstasy, amphetamines, cocaine, heroin, LSD, magic mushrooms and of new psychoactive substances), as well as gambling practices.

According to the study, alcohol consumption shows increases in lifetime prevalence, both among the total population (15-74 years) and among the young adult population (15-34 years), and among both men and women.

Tobacco consumption shows a slight rise in lifetime prevalence, which, according to the report, “is mainly due to increased consumption among women.”

The study also saw an increase from 8.3% in 2012, to 10.2% in 2016/17, in the prevalence of illegal psychoactive substance use. There were increases in both genders when considering the total population, a decrease among men and a rise among young adult women.

“These are the trends found for cannabis,” the most popular illegal substance, according to the provisional results of the study.

Compared to 2012, there is a later average onset age of consumption for alcohol, tobacco, drugs, amphetamines, heroin, LSD and hallucinogenic mushrooms.

Source: http://theportugalnews.com/news/alcohol-tobacco-and-drug-consumption-rise-over-last-five-years/43214 20th Sept.2017

[As illustrated in the Obituary of pioneering FDA scientist, Frances Oldham Kelsey in The Washington Post 8/8/15.]

THIS POST OBITUARY WAS A GODSEND, COMING JUST AS MANY POLITICAL LEADERS ARE BEGINNING A HEADLONG RUSH TO USURP FDA’S AUTHORITY TO APPROVE MARIJUANA-BASED MEDICINES IN FAVOR Of MONEY-CORRUPTED POLITICAL APPROVAL. THE ENDANGERED CITIZENRY, THEIR HEALTH PROFESSIONALS,POLITICAL LEADERS AND OBJECTIVE NEWS MEDIA JOURNALISTS , MUST STRONGLY RESIST THIS MISGUIDED ACTION BY POLTICIANS WHO ARE BLINDLY IGNORING THE HORRIFIC THALIDOMIDE PRECEDENT.

Edited excerpts with commentary follow: The full article is available at the following link:

http://www.washingtonpost.com/national/health-science/frances-oldham-kelsey-heroine-of-thalidomide-tragedy-dies-at-101/2015/08/07/ae57335e-c5da-11df-94e1-c5afa35a9e59_story.html

Frances Oldham Kelsey, FDA scientist who kept thalidomide off U.S. market, dies at 101

In the annals of modern medicine, it was a horror story of international scope: thousands of babies dead in the womb and at least 10,000 others in 46 countries born with severe deformities… The cause, scientists discovered by late 1961, was thalidomide, a drug that, during four years of commercial sales… was marketed to pregnant women as a miracle cure for morning sickness and insomnia.

The tragedy was largely averted in the United States, with much credit due to Frances Oldham Kelsey, a medical officer at the Food and Drug Administration in Washington, who raised concerns about thalidomide before its effects were conclusively known. For a critical 19-month period, she fastidiously blocked its approval while drug company officials maligned her as a bureaucratic nitpicker…

The global thalidomide calamity precipitated legislation…in October 1962 that substantially strengthened the FDA’s authority over drug testing. The new regulations, still in force, required pharmaceutical companies to conduct phased clinical trials, obtain informed consent from participants in drug testing, and warn the FDA of adverse effects, and granted the FDA with important controls over prescription-drug advertising…

In Washington, (Kelsey) joined a corps of reform-minded scientists who, although not yet empowered by the 1962 law that required affirmative FDA approval of any new drug, demanded strong evidence of effectiveness before giving their imprimatur.

At the time, a drug could go on the market 60 days after the manufacturer filed an application with the FDA… Meanwhile, pharmaceutical drug companies commonly supplied doctors with new drugs and encouraged them to test the product on patients, an uncontrolled and dangerous practice that relied almost entirely on anecdotal evidence. NICAP note: Much like today’s treatment of “medical marijuana.”

Thalidomide, which was widely marketed as a sedative as well as a treatment for pregnancy-related nausea during the first trimester of pregnancy, had proven wildly popular in Europe and a boon for its German manufacturer. NICAP note: Much like pro-pot propaganda today has created “wildly popular” support among a fact-deprived public, and boom-times for the Big Marijuana industry.

By the fall of 1960, a Cincinnati-based drug company, William S. Merrell, had licensed the drug and began to distribute it under the trade name Kevadon to 1,200 U.S. doctors in advance of what executives anticipated would be its quick approval by the FDA. NICAP note: Today, illegal drug companies produce and market hundreds of uncontrolled marijuana products and distribute them to corrupt doctors willing to “recommend” such unapproved marijuana “medicines.”

The Merrell application landed on Dr. Kelsey’s desk within weeks of her arrival at the agency…Immediately the application alarmed her. Despite what she called the company’s “quite fulsome” claims, the absorption and toxicity studies were so incomplete as to be almost meaningless. NICAP note: Much like the “quite fulsome claims” for pot medicines are legion today, as is the dearth of valid

studies verifying those claims. For the true documented scientific case against smoking weed as “medicine” see “The DEA Position on Marijuana” at link:

www.justice.gov/dea/docs/marijuana_position_2011.pdf

Dr. Kelsey rejected the application numerous times and requested more data. Merrell representatives, who had large potential profits riding on the application, began to complain to her bosses and show up at her office, with respected clinical investigators in tow, to protest the hold-up. NICAP note: Much as the Pot Legalization Lobbyists and ACLU show up at any attempts to limit sales and use of marijuana—and for the same reason: “large potential profits.”

Another reason for her concern was that the company had apparently done no studies on pregnant animals. At the time, a prevailing view among doctors held that the placental barrier protected the fetus from (harms from) what Dr. Kelsey once called “the indiscretions of the mother,” such as abuse of alcohol, tobacco or illegal drugs. Earlier in her career, however, she had investigated the ways in which drugs did in fact pass through the placenta from mother to baby… NICAP note: Today there are numerous valid studies showing that both mental and physical defects in children can be caused by a pregnant mother’s use of marijuana and other illegal drugs.

While Dr. Kelsey stood her ground on Kevadon, infant deaths and deformities were occurring at an alarming rate in places where thalidomide had been sold… NICAP note: Today, drug addiction, drug-related permanent disabilities and overdose deaths are “occurring at an alarming rate,” nearly all of which began with a shared joint of marijuana from a schoolmate or friend.

Dr. Kelsey might have remained an anonymous bureaucrat if not for a (previous) front-page story in The Post. The newspaper had received a tip about her from staffers working for Sen. Estes Kefauver, a Tennessee Democrat who had been stalled in his years-long battle with the pharmaceutical industry to bolster the country’s drug laws.

The coverage of Dr. Kelsey gave her — and Kefauver — a lift. As thousands of grateful letters flowed in to Dr. Kelsey from the public, the proposed legislation became hard to ignore or to water down. The new law was widely known as the Kefauver-Harris Amendments.

“She had a huge effect on the regulations adopted in the 1960s to help create the modern clinical trial system,” said Daniel Carpenter, a professor of government at Harvard University and the author of “Reputation and Power,” a definitive history of the FDA. “She may have had a bigger effect after thalidomide than before.”…

For decades, Dr. Kelsey played a critical role at the agency in enforcing federal regulations for drug development — protocols that were credited with forcing more rigorous standards around the world…

In Chicago, she helped Geiling investigate the 107 deaths that occurred nationwide in 1937 from the newly marketed liquid form of sulfanilamide, a synthetic antibacterial drug used to treat streptococcal infections. In tablet form, it had been heralded as a wonder-drug of the age, but it tasted unpleasant.

Because the drug was not soluble in water or alcohol, the chief chemist of its manufacturer, S.E. Massengill Co. of Bristol, Tenn., dissolved the sulfanilamide with an industrial substance that was a chemical relative of antifreeze. He then added cherry flavoring and pink coloring to remedy the taste and appearance.

Massengill rushed the new elixir to market without adequately testing its safety. Many who took the medicine — including a high number of children — suffered an agonizing death.

At the time, the FDA’s chief mandate, stemming from an obsolete 1906 law, was food safety. At the agency’s request, Geiling joined the Elixir Sulfanilamide investigation and put Dr. Kelsey to work on animal testing of the drug. She recalled observing rats as they “shriveled up and died.”

Amid national outrage over Elixir Sulfanilamide, Congress passed the Federal Food, Drug and Cosmetic Act of 1938, legislation that vastly expanded federal regulatory oversight over drugs and set a new benchmark for drug safety before marketing… NICAP note: Today, pro-pot politicians are rushing headlong into a massive campaign to block that objective FDA approval process for drugs and instead substitute a money-driven political process that will create a new “Thalidomide” out of marijuana and destroy many more American lives and futures.

Babies who suffered from the effects of thalidomide and survived grew up with a range of impairments. Some required lifelong home care… NICAP note: Is this to be the legacy of current politicians whose corrupt abandonment of the nation’s premier drug approval system will create generations of children “who suffered from the effects of POLITICAL APPROVED “medical” marijuana and survived with a range of impairments, some requiring lifelong home care?”

—————————————————————————————————————

Source: National Institute of Citizen Anti-drug Policy (NICAP)

NICAP COMMENTARY BY: DeForest Rathbone, Chairman.NICAP 8/9/15, Rev. 8/26/15

Neil McKeganey fears police are not as interested in cracking down on heroin any more SCOTLAND’S efforts to tackle its status as Europe’s worst drugs blackspot has been branded a “record of failure not success” by one of the country’s a leading drugs experts.

The Scottish Government’s flagship “Road to Recovery” strategy has not had any “marked impact” on drug abuse, according to Dr Neil McKeganey, director of the Centre for Drug Misuse research.

He also hits out at failures among local Alcohol and Drug partnerships (ADPs) to deliver on the ground and fears police are not as interested in cracking down on heroin any more as cocaine.

“It is not a lack of knowledge (although there are significant gaps in knowledge) that has truly hampered efforts at tackling Scotland’s drugs problem,” he states in a new essay.

“Rather there appears to have been successive shortcomings in the capacity to combine drug policy at the strategic level with a clear mechanism for implementation at the `street level.’”

The criticism has been published in a new booklet published by the Conservatives entitled Justice Matters.

Dr McKeganey also warns there are “very real concerns” at the way Scotland’s methadone programme is being used, with a lack of information about those on the programme and those leaving it drug free.

“Half of all drug deaths in Scotland are now linked to methadone compared to a figure of 14% in England” he adds.

Tory leader Ruth Davidson said the booklet sets out “straightforward, no-nonsense Conservative policies that reflect the concerns of mainstream Scotland.”

She added: “Our aim is to cut crime and anti-social behaviour, make our communities safer and improve the quality of life for ordinary Scots.”

Source: http://www.scotsman.com/news/politics/top-stories/scotland-s-war-on-drugs-is-a-record-of-failure-1-3665809  19th Jan.2015

2015 will be remembered as the year legalization hit bumps most supporters never anticipated.

For pro-health advocates that oppose marijuana legalization, it was a year of fantastic victories! Here are the top 10:

10. Big Marijuana is Real — and People are Writing About It.

When we started talking about Big Marijuana in 2013, many people laughed. Could marijuana even be compared with Big Tobacco in any credible way? But now, that’s ancient history. Several articles – even in legalization-friendly blogs like this one – mention the term. And the term is not just rhetoric — the most senior federal legalization lobbyist in the country resigned in protest because, in his words, “industry was taking over the legalization movement.” Not only was that heroic of him, it was historic for us.

9. Continuing Positive Press Coverage of Groups Opposing Legalization. 

With the exception of some very pro-pot columnists, this year represented one in which our side was represented just a little bit better than in the past. A profile of SAM was featured in the International Business Times, and other articles continued to broadcast our message to new audiences.

With the hiring of a new Communications Director in 2016, you can bet we won’t let up on this next year.

8. Several States Resisted Full-Blown Legalization. 

We entered 2014 after setbacks in Alaska and Oregon; but we stuck to winning messages and formed coalitions in a bloc of New England states that were all under attack in the early part of 2015. From Maine to Massachusetts to New Hampshire to Rhode Island, our partners and affiliates fought back —- and not one state legalized via legislature as the legalizers had promised. We’ll be taking this momentum into 2016.

7. Lawyering Up.

 Many of our friends made strong statements in court — “Colorado and other states cannot legalize in the face of federal law,” they argue. Of course we know they are right, and we know that regardless of legal outcomes the statement they sent was loud and clear. (We’re also happy that the Justice Department, in its opposition to the suit, solely argued against it on procedural grounds — they did not substantively come out in favor of legalization to the Solicitor General). The plaintiff’s bar should take notice—just like Big Tobacco became a big target for lawsuits, Big Marijuana and those who sell the drug will, too.

6. Marijuana Stores Banned in California, Washington, Colorado, Oregon, Michigan, and Elsewhere. 

Despite legalization in some states, we know that local ordinances are one of the key strategies to keeping marijuana out of communities. The majority of towns in most weed-friendly states have indeed banned stores altogether. Even in Detroit, up to half of Detroit’s roughly 150 medical marijuana dispensaries could close following a Detroit City Council vote to approve a restrictive zoning ordinance. We will keep pushing hard for more bans in 2016.

5. Legalizers Made No Gains in Congress This Year
.

 For the past decade, it seemed that every year we lost a little more in Congress. Not in 2015. Despite the most aggressive lobbying effort yet by pro-marijuana folks, they made no progress on key provisions:

· They wanted to give tax breaks to pot shops—just like Big Tobacco lobbies to lower taxes on cigarettes.

  • They wanted to allow pot businesses to leverage Wall Street money through the banking system.
  • They wanted to stop the Justice Department from enforcing the law in states with legalized recreational marijuana.
  • They wanted to give pot to our most vulnerable citizens to “treat” PTSD — even though science says marijuana makes PTSD, as well as other mental illness, worse.
  • They wanted Washington, DC, to become a mecca for Big Marijuana.

And we won – on every issue.

4. Continued Support from ONDCP, DEA, and NIDA.

2015 was a transitional year for key federal drug policy agencies. A new ONDCP Director was appointed — and even though we are still waiting for the Obama Administration to enforce federal law, it is clear where Director Botticelli’s heart is. Right after getting into office, the Director sat down with me for a one-to-one on-the-record interview where he blasted legal pot. And only a few weeks ago, he was featured on 60 Minutes talking about the harms of marijuana and the harms of the industry.

Additionally, we saw the appointment of a new DEA Administrator — this time from the FBI. Administrator Rosenberg has been an excellent leader by moving to support legitimate medical research over faux claims of “medical” marijuana.

And we continue to receive support from NIDA Director Nora Volkow, who headlined SAM’s summit last year, for her unwavering support of public health above profits. 

3. Real Progress on Researching the Medical Components of Marijuana.

 I’m proud that SAM took a bold stand this year to defend the legitimate research of medical components of marijuana. And our ground-breaking report paid off. The federal government has already adopted two of the report’s provisions — eliminating the Public Health Service review and getting rid of onerous CBD handling requirements. We will continue to fight for legitimate marijuana research, and to separate it from faux medicine-by-ballot-initiative. 

2. No States Legalized “Medical” Marijuana in 2015.

This is a big one, given where the country is on the “medical” marijuana issue. No state legalized the drug for medical purposes this year, despite several tries in key states. Even in Georgia, where legalizers have been emboldened by a few pot-friendly legislators, a government-convened panel voted to follow science and impose sensible restrictions on the drug. 

1. Ohio! 

Of course, the victory in Ohio tops the field. Despite being outspent 12-to-1, our affiliates and partners brought us a huge victory in November. We plan to build on this for 2016, but we need your help.

Despite the nonstop talking point of “inevitability,” we know that the 8% of Americans who use pot don’t speak for 92% of Americans that don’t want to see Big Tobacco 2.0, don’t want to worry about another drug impairing drivers on the road, and don’t want to think about keeping things like innocuous-looking “pot gummy bears” away from their kids. We know that the pot lobby will work hard for things like not only full-blown legalization in several more states next year, but also things like on-site pot smoking “bars” (they are really proposing these in Alaska and Colorado as we speak) and an expansion of pot edibles.

In 2016, let’s nip Big Marijuana in the bud.

Source: https://www.huffingtonpost.com/kevin-a-sabet-phd/top-10-antimarijuana-lega_b_8879338.html

Priorities for Reform of UK Drug Policy : Policy-UK Forum

Dear Mr Marsh.

Thank you for the invitation. I shall not be attending.

You have included in the Speakers Niamh Eastwood & Mike Trace, both people who push drugs legalisation. I have debated publicly with both. Their positions are well known. I do not take either seriously as unbiased commentators on drugs policy. I doubt government does either. I regard both as paid apostles of a particular point of view. A point of view which is not shared by most MPs or members of the public.

In Mike’s case, he was, in his own word “disgraced”, when forced to resign from his then new job at the UN, when he was exposed as  being (again in his own words), “a fifth columnist”, for the George Soros financed, “Open Society”, worldwide, drug legalisation campaign, (of all possible drugs) . Release has been similarly supported by Soros and was named in Mr Trace’s covert plan on this subject, when it was exposed several years ago..

Given those two speakers, your conference seems to me, to be just another platform for the legalisation lobby, not a genuine, open and serious debate, which can improve policy making or add significant value.

That legalisation lobby has lost the debate in the U.K. The starting point was the exposing of Mike Trace. Further debate involving these two very discredited speakers (discredited by association), is in my view pointless. The drug legalisation debate in the U.K, is over. The Psychoactive Substances Bill, approaching 3rd reading, also overtakes some of your agenda.

Thank you for the invitation.

David Raynes

NDPA

Source: Response to invitation to

UK Drugs Policy – Criminal Justice, Public Health and the Psychoactive Substances Bill

Policy-UK Forum, letter from David Raynes, consultant and media spokesman for NDPA.

Sent January 2016.

 

 

Legalizing opioids may give Americans greater freedom over their decision-making, but at what cost? One painful aspect of the public debates over the opioid-addiction crisis is how much they mirror the arguments that arise from personal addiction crises.

If you’ve ever had a loved one struggle with drugs — in my case, my late brother, Josh — the national exercise in guilt-driven blame-shifting and finger-pointing, combined with flights of sanctimony and ideological righteousness, has a familiar echo. The difference between the public arguing and the personal agonizing is that, at the national level, we can afford our abstractions.

When you have skin in the game, none of the easy answers seem all that easy. For instance, “tough love” sounds great until you contemplate the possible real-world consequences. My father summarized the dilemma well. “Tough love” — i.e., cutting off all support for my brother so he could hit rock bottom and then start over — had the best chance of success. It also had the best chance for failure — i.e., death. There’s also a lot of truth to “just say no,” but once someone has already said “yes,” it’s tantamount to preaching “keep your horses in the barn” long after they’ve left.

But if there’s one seemingly simple answer that has been fully discredited by the opioid crisis, it’s that the solution lies in wholesale drug legalization. In Libertarianism: A Primer, David Boaz argues that “if drugs were produced by reputable firms, and sold in liquor stores, fewer people would die from overdoses and tainted drugs, and fewer people would be the victims of prohibition-related robberies, muggings and drive-by-shootings.”

Maybe. But you know what else would happen if we legalized heroin and opioids? More people would use heroin and opioids. And the more people who use such addictive drugs, the more addicts you get. Think of the opioid crisis as the fruit of partial legalization. In the 1990s, for good reasons and bad, the medical profession, policymakers, and the pharmaceutical industry made it much easier to obtain opioids in order to confront an alleged pain epidemic. Doctors prescribed more opioids, and government subsidies made them more affordable. Because they were prescribed by doctors and came in pill form, the stigma reserved for heroin didn’t exist. When you increase supply, lower costs, and reduce stigma, you increase use.

And guess what? Increased use equals more addicts. A survey by the Washington Post and the Kaiser Family Foundation found that one-third of the people who were prescribed opioids for more than two months became addicted. A Centers for Disease Control study found that a very small number of people exposed to opioids are likely to become addicted after a single use. The overdose crisis is largely driven by the fact that once addicted to legal opioids, people seek out illegal ones — heroin, for example — to fend off the agony of withdrawal once they can’t get, or afford, any more pills. Last year, 64,000 Americans died from overdoses. Some 58,000 Americans died in the Vietnam War.

Experts rightly point out that a large share of opioid addiction stems not from prescribed use but from people selling the drugs secondhand on the black market, or from teenagers stealing them from their parents. That’s important, but it doesn’t help the argument for legalization. Because the point remains: When these drugs become more widely available, more people avail themselves of them. How would stacking heroin or OxyContin next to the Jim Beam lower the availability? Liquor companies advertise — a lot. Would we let, say, Pfizer run ads for their brand of heroin? At least it might cut down on the Viagra commercials. I think it’s probably true that legalization would reduce crime, insofar as some violent illegal drug dealers would be driven out of the business.

I’m less sure that legalization would curtail crimes committed by addicts in order to feed their habits. As a rule, addiction is not conducive to sustained gainful employment, and addicts are just as capable of stealing and prostitution to pay for legal drugs as illegal ones. The fundamental assumption behind legalization is that people are rational actors and can make their own decisions. As a general proposition, I believe that. But what people forget is that drug addiction makes people irrational. If you think more addicts are worth it in the name of freedom, fine. Just be prepared to accept that the costs of such freedom are felt very close to home.

Source: http://www.nationalreview.com/article/453304/opioid-crisis-legalization-not-solution

 

Legalisation of cannabis is likely to lack priority for this new government.

There is one benefit to MMP, it is that the whackier campaign ideas tend to perish in the coalition negotiation process.

That hasn’t entirely been the case this time, the worst example being the Green Party’s promise to initiate a referendum on the subject of legalising cannabis (by 2020).

This would seem to be a case of a party formulating policy in the hope that it will garner votes as opposed to genuinely believing it will be beneficial. That view is reinforced by Green leader James Shaw’s assurance last week that he had never smoked cannabis, adding the illuminating comment, “It isn’t good for you, is it?”

“We know that cannabis is a carcinogenic, as is tobacco. Unlike tobacco, however, it is also linked, beyond dispute, with mental illness and poor academic achievement.”

Too right it isn’t. There is enough evidence to support that to stupefy an entire nation, which makes it all the more extraordinary that he would not only propose a referendum in the first place, but would stick to his guns when it came to striking a deal with Labour.

All the more extraordinary because Mr Shaw’s party is one of the leading lights in the drive to make New Zealand tobacco-free by 2025. (Presumably the term smoke-free is now redundant).

If all goes according to his plan, a substance that harms the physical health of the user will disappear just in time to be replaced by another substance that does even more damage, physically, emotionally and intellectually, than tobacco ever has.

We know that cannabis is a carcinogenic, as is tobacco. Unlike tobacco, however, it is also linked, beyond dispute, with mental illness and poor academic achievement. From there it can be held accountable for reducing the user’s ability to find employment, and everything that goes with that, including poverty, for themselves and their dependents.

The drive for legalisation has taken a turn (for the worse) this time around because of strident appeals to recognise its medicinal benefits. It might well dull pain – it certainly dulls most of the user’s senses – but there is a undoubtedly deliberate blurring of the lines by the drug’s supporters between medicinal cannabis, which does not include its mind-altering properties, and the ‘benefits’ to be gained by allowing its cultivation/possession and consumption in the traditional manner.

People have long waxed eloquent about cannabis as a pain killer, usually from the dock as they are in the process of being sentenced for growing the stuff. If personal experience of that is anything to go by, its fans tend to show all the signs of long-term use, which might make them happy but has reduced their role in society to that of passengers.

It might well be true that cannabis does not represent any great threat to the physical or mental health of a middle-aged dope smoker who indulges on an occasional basis. The same cannot be said for those who start young, and there, Mr Shaw, lies the rub.

We have been told for years, most often by the National Organisation for the Reform of Marijuana Laws (Norml – there’s an oxymoron for you) that legalisation would of course need to be accompanied by strict controls that would keep it out of the hands of young people.

That assurance has been given to the writer on numerous occasions, but no one has ever been able to explain how any such measures would stand any chance of success, given our experience with tobacco and alcohol.

Neither of those substances may be legally purchased or used by minors, but both are. No one in this country has yet been able to devise controls that prevent that, and the same, inevitably, will apply to cannabis. Prove to us that you have cracked that, Mr Shaw, and people might start listening to you.

The best reason for not legalising cannabis was offered to this newspaper some years ago by a teacher at Kaitaia College. He said the college was home to any number of bright, determined, ambitious young people who knew what they wanted to do with their lives, and had mapped out exactly how they were going to achieve their ambitions.

They knew that even a minor cannabis conviction would nobble those ambitions, and for that reason alone wouldn’t touch the stuff with a barge pole.

No one the writer knows has ever come up with a better reason for not legalising it. And no one will. If it is legalised future generations of bright, ambitious young people will assuredly dabble in it, to their (and our) cost.

Even if they don’t succumb to regular use it will rob them, to some degree, of their potential, to a far greater degree than flirting with alcohol or tobacco ever would.

We don’t hear Mr Shaw, or anyone else, suggesting that our children should have greater access than they already do to alcohol and tobacco, for good reason. How they can be prepared to countenance access to cannabis defies explanation.

Perhaps Mr Shaw’s political interest in this issue outweighs any concern he might have for future generations. Perhaps the legalising of cannabis has such appeal to his voter base that he can accept the inevitable collateral damage. Hopefully he is in a very small minority, and will remain so.

And don’t buy the hoary old story that our prisons are full of people who wouldn’t be there if cannabis was legal. Those who insist that this is true have either been doing too much personal research into the ‘benefits’ of sucking on cannabis cigarette all day or are deliberately trying to deceive.

No one is in jail in this country today purely because they have been caught using cannabis. One or two might be there because they were caught growing or dealing it on a substantial scale, but possession of cannabis, whatever the law might say, is no longer an imprisonable offence in this country, and hasn’t been for a very long time.

There will be some who are in jail on convictions that include possession of cannabis, but it won’t have been the drug that put them behind bars. They will have offended in other ways. To say that people are in jail because of personal possession is a blatant lie.

Some elements of the current debate are certainly worth pursuing, including that drug addiction in general should be regarded as a health issue rather than a criminal matter. And there is no doubt that drug treatment facilities are woefully inadequate. But again, this is where the pro-cannabis logic collapses.

We know the harm cannabis does; we know it leads to dependence on much harsher chemical substances; we know that people who become addicted, to whatever substance, are unlikely to get the help they need to get off it. And we know that the damage done, by cannabis and other drugs, is permanent. Dead brain cells don’t grow back.

Yet here we are talking about legalising it. It makes no sense whatsoever to even consider it. A handful of people might genuinely believe that it will ease their pain, or, in medical form, will reduce the severity of some far from common conditions (again, the use of medical marijuana is a separate issue), but legalising cannabis for all and sundry will not benefit society in any imaginable way.

There can be absolutely no question that legalising cannabis will, in fact, do enormous harm, and any politician who is unaware of that, or is prepared to trade that harm for electoral success, has no place in Parliament.

Source:http://www2.nzherald.co.nz/northland-age/opinion/news/article.cfm?c_id=1503399&objectid=11938825-

Back to top of page

Powered by WordPress